Author’s response to reviews Title: Addition of nucleoside analogues to Peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to Peg-IFNα-2a: A randomized controlled trial
نویسندگان
چکیده
Title: Addition of nucleoside analogues to Peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to Peg-IFNα-2a: A randomized controlled trial Authors: yan xu ([email protected]) xu wang ([email protected]) zhenhua liu ([email protected]) Changyu Zhou ([email protected]) wenqian qi ([email protected]) jian jiao ([email protected]) fan yu ([email protected]) honghua guo ([email protected]) ping zhao ([email protected]) Jiangbin Wang ([email protected]) Version: 2 Date: 06 Apr 2017 Author’s response to reviews: Replies to recommendations on revision 1. Please include the institutional addresses of all authors on the title page of your manuscript. The institutional addresses of all authors has been added(the title page, line 6, page 1).
منابع مشابه
Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial
BACKGROUND Current treatments for chronic hepatitis B (CHB) include pegylated interferon alpha (PEG-IFN-α) which is an immune modulator, and nucleos(t)ide analogs (NAs) which directly inhibit HBV DNA polymerase. With the limited efficacy of PEG-IFN-α and prolonged treatment periods associated with NAs, there is an urgent need for novel therapeutic strategies, especially for patients with a poor...
متن کاملSafety and Efficacy of Pegylated Interferon Alfa-2a for the Treatment of Hepatitis C in Patients with Major Thalassemia
Background: Hepatitis C virus (HCV) infection is the most common transfusion transmitted disease in poly-transfused patients worldwide. In this study we aimed to evaluate the effects of pegylated interferon alfa-2a (PEG-IFN A-2a) in reducing serum ALT and eradicating serum hepatitis C virus (HCV) RNA in HCV infected polytransfused thalassemic patients. Materials and Methods: A cohort of 51 HCV-...
متن کاملThe Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients
BACKGROUND The hepatitis C virus (HCV) infection has been identified as a leading cause of progressive liver diseases worldwide. Despite new treatment strategies, pegylated interferon alfa-2a (Peg-IFNα-2a), in combination with ribavirin (RBV), still represents the gold standard of therapy for hepatitis C in developing countries. OBJECTIVES The aim of this study was to investigate the associat...
متن کاملEfficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis
BACKGROUND Two formulations of Pegylated interferon (Peg-IFN) are on the market for treatment of chronic hepatitis C virus (HCV) infection. The purpose of this meta-analysis was to assess the efficacy of Peg-IFN α-2a versus Peg-IFN α-2b in combination with ribavirin in anti-human immunodeficiency virus (HIV)-negative patients with genotype 1 chronic HCV infection. METHODS The following criter...
متن کاملCD3brightCD56+ T cells associate with pegylated interferon-alpha treatment nonresponse in chronic hepatitis B patients
Chronic hepatitis B (CHB) infection is a serious and prevalent health concern worldwide, and the development of effective drugs and strategies to combat this disease is urgently needed. Currently, pegylated interferon-alpha (peg-IFNα) and nucleoside/nucleotide analogues (NA) are the most commonly prescribed treatments. However, sustained response rates in patients remain low, and the reasons ar...
متن کامل